Bacterial vaccines in development 2

Published on September 30, 2015   38 min

You are viewing a talk that is a part of one of our comprehensive courses. Additional learning material: case studies, projects, workshops and recommended reading; multiple choice questions and suggested exam questions with model answers are available on application. Learn more

Other Talks in the Series: Vaccines

I will now move on to describe vaccines in development against a highly complex pathogen, Staphylococcus aureus. This pathogen causes disease by expressing a number of virulence factors.
S. aureus causes the wide spreading of diseases ranging from relatively mild skin infections to life threatening wound and bloodstream infections. It is a leading cause of morbidity and mortality in both health care-associated and community settings. In surgical patients, S. aureus infections are associated with high morbidity and mortality, prolongation of hospital stays, and an increase in health care costs. We also noted increases of antibotic resistance, most notably, meticillin resistance. There is an alarming increase in community acquired infections as well, in many settings, including pediatric populations. And I also listed on this slide, populations that are at high risk of S. aureus infection.